[18F]-Fallypride ((S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3[18F]fluoropropyl)-2,3-dimethoxybenzamide) was produced in the radiochemistry laboratory attached to the PET unit at Vanderbilt University Medical Center, following synthesis and quality control procedures described in the US Food and Drug Administration IND 47 245. All the data were collected on the same GE Discovery STE PET scanner.
Serial scan acquisition was started simultaneously with a 5.0 mCi (185 MBq) slow bolus injection of DA D2/3 tracer [18F]-Fallypride (specific activity >3000 Ci mmol−1). Computed tomographic scans were collected for attenuation correction before each of the three emission scans, which together lasted approximately 3.5 h with two breaks for subject comfort. Acquisition times for the dynamic PET scans were the same across all studies and have been reported previously.51 (link)
Serial scan acquisition was started simultaneously with a 5.0 mCi (185 MBq) slow bolus injection of DA D2/3 tracer [18F]-Fallypride (specific activity >3000 Ci mmol−1). Computed tomographic scans were collected for attenuation correction before each of the three emission scans, which together lasted approximately 3.5 h with two breaks for subject comfort. Acquisition times for the dynamic PET scans were the same across all studies and have been reported previously.51 (link)
